Related Experiment Video
Updated: Apr 25, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
The Israel Diabetes and Cognitive Decline (IDCD) study: Design and baseline characteristics
Michal Schnaider Beeri1, Ramit Ravona-Springer2, Erin Moshier3
1Departments of Psychiatry and Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA; Departments of Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA; Department of Psychiatry, Sheba Medical Center, The Joseph Sagol Neuroscience Center, Tel-Aviv, Israel.
Background:
Type 2 diabetes (T2D) is associated with increased risk of dementia. The prospective longitudinal Israel Diabetes and Cognitive Decline study aims at identifying T2D-related characteristics associated with cognitive decline.
Methods:
Subjects are population-based T2D 65+, initially cognitively intact. Medical conditions, blood examinations, and medication use data are since 1998; cognitive, functional, demographic, psychiatric, DNA, and inflammatory marker study assessments were conducted every 18 months. Because the duration of T2D reflects its chronicity and implications, we compared short (0-4.99 years), moderate (5-9.99), and long (10+) duration for the first 897 subjects.
Results:
The long duration group used more T2D medications, had higher glucose, lower glomerular filtration rate, slower walking speed, and poorer cognitive functioning. Duration was not associated with most medical, blood, urine, and vital characteristics.
Conclusions:
Tracking cognition, with face-to-face evaluations, exploiting 15 years of historical detailed computerized, easily accessible, and validated T2D-related characteristics may provide novel insights into T2D-related dementia.
More Related Videos
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
06:21Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
Published on: April 7, 2023
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Type I Diabetes III: Clinical Manifestations
Type II Diabetes I: Introduction
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Alzheimer Disease l: Introduction
Type I Diabetes I: Introduction